Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Cell

Volumn 140, Issue 2, 2010, Pages 209-221

  Heidorn, Sonja J ^a   Milagre, Carla ^a   Whittaker, Steven ^a   Nourry, Arnaud ^a   Niculescu Duvas, Ion ^a   Dhomen, Nathalie ^a   Hussain, Jahan ^b   Reis Filho, Jorge S ^a   Springer, Caroline J ^a   Pritchard, Catrin ^b   Marais, Richard ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

HUMDISEASE; PROTEINS; SIGNALING

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 885 A; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONCOPROTEIN; PLX 4720; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SORAFENIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; TUMOR GROWTH;

MUS;

EID: 74849109743     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2009.12.040     Document Type: Article

References (32)

1. Cameron A.J., Escribano C., Saurin A.T., Kostelecky B., and Parker P.J. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat. Struct. Mol. Biol. 16 (2009) 624-631
2. Dankort D., Curley D.P., Cartlidge R.A., Nelson B., Karnezis A.N., Damsky Jr. W.E., You M.J., DePinho R.A., McMahon M., and Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41 (2009) 544-552
3. Dhomen N., Reis-Filho J.S., da Rocha Dias S., Hayward R., Savage K., Delmas V., Larue L., Pritchard C., and Marais R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15 (2009) 294-303
4. Dumaz N., Hayward R., Martin J., Ogilvie L., Hedley D., Curtin J.A., Bastian B.C., Springer C., and Marais R. In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling. Cancer Res. 66 (2006) 9483-9491
5. Fabian J.R., Vojtek A.B., Cooper J.A., and Morrison D.K. A single amino acid change in Raf-1 inhibits Ras binding and alters Raf-1 function. Proc. Natl. Acad. Sci. USA 91 (1994) 5982-5986
6. Flaherty K., Puzanov I., Sosman J., Kim K., Ribas A., McArthur G., Lee R.J., Grippo J.F., Nolop K., and Chapman P. Phase I study of PLX4032: Proof of concept for V600EBRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27 (2009) 15s
7. Frye S.V., and Johnson G.L. Inhibitors paradoxically prime kinases. Nat. Chem. Biol. 5 (2009) 448-449
8. Garnett M.J., and Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6 (2004) 313-319
9. Garnett M.J., Rana S., Paterson H., Barford D., and Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20 (2005) 963-969
10. Gray-Schopfer V., Wellbrock C., and Marais R. Melanoma biology and new targeted therapy. Nature 445 (2007) 851-857
11. Halilovic E., and Solit D.B. Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr. Opin. Pharmacol. 8 (2008) 419-426
12. Hall-Jackson C.A., Eyers P.A., Cohen P., Goedert M., Boyle F.T., Hewitt N., Plant H., and Hedge P. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6 (1999) 559-568
13. Ikenoue T., Hikiba Y., Kanai F., Tanaka Y., Imamura J., Imamura T., Ohta M., Ijichi H., Tateishi K., Kawakami T., et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res. 63 (2003) 8132-8137
14. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoay R., Jacks T., and Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15 (2001) 3243-3248
15. Johnson L.N., Lowe E.D., Noble M.E., and Owen D.J. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett. 430 (1998) 1-11
16. King A.J., Patrick D.R., Batorsky R.S., Ho M.L., Do H.T., Zhang S.Y., Kumar R., Rusnak D.W., Takle A.K., Wilson D.M., et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66 (2006) 11100-11105
17. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 351 (2000) 289-305
18. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80 (1995) 179-185
19. Mason C.S., Springer C.J., Cooper R., Superti-Furga G.T., Marshall C.J., and Marais R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J. 18 (1999) 2137-2148
20. Meuwissen R., Linn S.C., van der Vald M., Mooi W.M., and Berns A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20 (2001) 6551-6558
21. Montagut C., Sharma S.V., Shioda T., McDermott U., Ulman M., Ulkus L.E., Dias-Santagata D., Stubbs H., Lee D.Y., Singh A., et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68 (2008) 4853-4861
22. Okuzumi T., Fiedler D., Zhang C., Gray D.C., Aizenstein B., Hoffman R., and Shokat K.M. Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 5 (2009) 484-493
23. Rajakulendran T., Sahmi M., Lefrançois M., Sicheri F., and Therrien M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461 (2009) 542-545
24. Rushworth L.K., Hindley A.D., O'Neill E., and Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 26 (2006) 2262-2272
25. Schwartz G.K., Robertson S., Shen A., Wang E., Pace L., Dials H., Mendelson D., Shannon P., and Gordon M. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. J. Clin. Oncol. 27 (2009) 15s
26. Sebolt-Leopold J.S., Dudley D.T., Herrera R., Van Becelaere K., Wiland A., Gowan R.C., Tecle H., Barrett S.D., Bridges A., Przybranowski S., et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 5 (1999) 810-816
27. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 105 (2008) 3041-3046
28. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., and Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
29. Weber C.K., Slupsky J.R., Kalmes H.A., and Rapp U.R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61 (2001) 3595-3598
30. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Zhang X., Vincent P., McHugh M., Cao Y., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets RAF/MEK/ERK pathway and receptor tyrosine kinase involved in tumor progression and angiogeneisis. Cancer Res. 64 (2004) 7099-7109
31. Workman P., Balmain A., Hickman J.A., McNally N.J., Rohas A.M., Mitchison N.A., Pierrepoint C.G., Raymond R., Rowlatt C., Stephens T.C., et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab. Anim. 22 (1988) 195-201
32. Yajima I., Belloir E., Bourgeois Y., Kumasaka M., Delmas V., and Larue L. Spatiotemporal gene control by the Cre-ERT2 system in melanocytes. Genesis 44 (2006) 34-43